DJIA 17,778.15 421.28 2.43%
NASDAQ 4,748.40 104.08 2.24%
S&P 500 2,061.23 48.34 2.40%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)



company name or ticker

Why I Won't Buy Ebola Stocks

The share prices of companies leading the fight against Ebola have been soaring lately. Is this investor enthusiasm justified?

Ebola: The making of a $1 billion drug

Could Sarepta Therapeutics Inc. Be Running Out of Money?

A biotech stock running out of money is a worry that healthcare investors don't take lightly. Let's take a closer look at clinical-stage drug developer Sarepta Therapeutics and discover whether or not it has enough cash in its coffers to execute on its business strategy.

Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta

New Ebola Fears in NYC Make Major Ebola Stock Waves

Some Potential Targets for Shire to Buy With $1.6B in Free Money

Ebola Stock Fallout Severe on Monday

Should Ebola Fear... Tobacco?

Ebola vaccine production could get a lift thanks to tobacco plants.

Detailed Analysis Of Sarepta's Ebola Virus Cocktail: Full Phase I Clinical Trial Analysis For Non-Sc

Detailed Analysis Of Sarepta's Ebola Virus Cocktail: Full Phase I Clinical Trial Analysis For Non-Scientists

Sector Update: Strong Advance for Health Care Sector; Sarepta Therapeutics Up After Positive Results

Sector Update: Strong Advance for Health Care Sector; Sarepta Therapeutics Up After Positive Results for Possible Ebola Treatment
See More Articles...